Oruka Therapeutics Reports Positive Week 16 ORKA-001 Results in Psoriasis Trial

What happened

Oruka Therapeutics said 61% of high-dose ORKA-001 patients achieved complete skin clearance at Week 16 in its Phase 2b EVERLAST-B psoriasis trial, versus 0% on placebo. High-dose patients also had 86% PASI 90 and IGA 0/1 response rates, with favorable safety.

Confirmed

Global impact / market context

Clear, placebo-beating skin clearance results could support ORKA-001's path toward Phase 3 testing and eventual regulatory filing, which matters for a drug developer with no approved product. Strong efficacy and low serious adverse events may improve partnering or financing discussions.

Analyst inference

Oruka reported $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026, expected to fund operations through an anticipated ORKA-001 BLA filing. That cash runway, which means available money to fund spending, reduces near-term financing pressure while Phase 3 planning proceeds.

Analyst inference

What to watch

1. Oruka plans to begin Phase 3 trials in the first half of 2027, subject to regulatory discussions, so timing depends on health regulators agreeing on trial design. Confirmed
2. Watch whether Oruka advances ORKA-001 into Phase 3 as proposed and whether it discloses additional trial details or regulatory feedback affecting study start dates. Proposed
3. Track cash spending against the $1.1 billion reported, because Phase 3 trials are costly and a faster burn could shorten the runway expected to last through a BLA filing. Analyst inference

Evidence

• Original source link unavailable